Navicare Biotech , Ltd. Profit Margin

Navicare Biotech , Ltd. (8472.TWO) currently reports a profit margin of -2.26% as of June 2026. That compares with -15.28% in the prior-year period — up 85.2% year over year. That is below the sector sector average of 13.2%. Use the charts on this page to explore Navicare Biotech , Ltd.'s profit margin history and peer comparisons.

Navicare Biotech , Ltd.'s profit margin increased from -15.28% to -2.26% — a 85.2% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Navicare Biotech , Ltd.'s profit margin of -2.26% is lower than the its sector sector average of 13.2%. That is roughly 117.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Navicare Biotech , Ltd.'s current -2.26% should be judged against industry norms (sector average: 13.2%) and against 8472.TWO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -2.26%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 13.2%. From there, open related valuation or income-statement pages for Navicare Biotech , Ltd., and consider following 8472.TWO for alerts when major investors trade the stock.